Priscilla K Brastianos

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Primary central nervous system lymphoma: overview of current treatment strategies
    Priscilla K Brastianos
    Stephen E and Catherine Pappas Center for Neuro Oncology, Division of Hematology and Oncology, Department of Neurology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Hematol Oncol Clin North Am 26:897-916. 2012
  2. ncbi Vascular endothelial growth factor inhibitors in malignant gliomas
    Priscilla K Brastianos
    Stephen E and Catherine Pappas Center for Neuro Oncology, Department of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Target Oncol 5:167-74. 2010
  3. ncbi The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Smith 353, Boston, MA 02115, USA
    J Neurooncol 106:81-8. 2012
  4. ncbi VEGF inhibitors in brain tumors
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, Massachusetts General Hospital, Boston, 02114, USA
    Clin Adv Hematol Oncol 7:753-60, 768. 2009

Collaborators

Detail Information

Publications4

  1. ncbi Primary central nervous system lymphoma: overview of current treatment strategies
    Priscilla K Brastianos
    Stephen E and Catherine Pappas Center for Neuro Oncology, Division of Hematology and Oncology, Department of Neurology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Hematol Oncol Clin North Am 26:897-916. 2012
    ..The standard treatment is a methotrexate-containing chemotherapy regimen. The timing and dose of whole-brain radiation therapy is controversial, given the significant risks of late neurotoxic effects, particularly in elderly patients...
  2. ncbi Vascular endothelial growth factor inhibitors in malignant gliomas
    Priscilla K Brastianos
    Stephen E and Catherine Pappas Center for Neuro Oncology, Department of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Target Oncol 5:167-74. 2010
    ..Unfortunately, antiangiogenic treatment inevitably fails in most patients. Further studies are needed to understand the molecular pathways that enable a tumor to evade antiangiogenic therapy...
  3. ncbi The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Smith 353, Boston, MA 02115, USA
    J Neurooncol 106:81-8. 2012
    ..This neurotoxicity study provides safety data to allow phase I/II studies in humans with treatment refractory LC...
  4. ncbi VEGF inhibitors in brain tumors
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, Massachusetts General Hospital, Boston, 02114, USA
    Clin Adv Hematol Oncol 7:753-60, 768. 2009
    ..Unfortunately, treatment inevitably fails. Further studies are needed to understand mechanisms of tumor resistance and to identify other therapeutic targets that mediate angiogenesis...